ClinicalTrials.gg
RecruitingNCT06230614Updated Nov 9, 2026

Effect of Diluent Volume on Colistin Inhalation Therapy

An interventional study of Colistin 1 MU in normal saline 1 ml and Colistin 1 MU in normal saline 2 ml in Inhalation Pneumonia, sponsored by Fu Jen Catholic University. Recruiting at 1 site in Taiwan. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Fu Jen Catholic University · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Mar 2024; still recruiting 2 years 8 months later.
Updated Nov 9, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 100 Years
Sex
All
01

Study summary

The aim of this study is to investigate the impact of different diluent volumes for the same dosage of colistin in mechanically ventilated respiratory patients receiving colistin inhalation therapy. The study aims to determine whether the diluent volume has an effect on clinical outcomes, including ICU length of stay, total hospitalization duration, duration of respiratory support within 28 days, mortality rates within 28 days and 90 days, as well as analyze the pharmacokinetic profile of colistin in blood and bronchoalveolar lavage fluid. Additionally, the study will evaluate the incidence of nebulizer malfunctions and blockages. The findings of this research will help identify the optimal diluent volume for colistin inhalation therapy in clinical practice.

Read the detailed description

Background: Colistin is an antibiotic used to treat infections caused by multidrug-resistant Gram-negative bacteria. In recent years, it has been widely utilized as an inhaled antibiotic for the treatment of respiratory infections in critically ill patients on mechanical ventilation. Despite the increasing use of colistin inhalation therapy for ventilator-associated pneumonia, the clinical impact of diluent volume on nebulization efficiency remains unclear.

Study Design: A single-center, prospective, randomized controlled trial.

Methods: The study plans to enroll 60 participants. Colistin inhalation therapy will be administered using a blocked stratified random allocation. The control group will receive colistin 6 MU diluted in 6 ml of normal saline (1 MU per 1 ml), while the experimental group will receive colistin 6 MU diluted in 12 ml of normal saline (1 MU per 2 ml). The dosage, frequency, and administration method of colistin inhalation will follow the clinical standard of 6 MU, administered every 8 hours, continuously for 7 days.

Effect: The investigators anticipate that the clinical outcomes and pharmacokinetics of colistin inhalation therapy will not differ significantly between different diluent volumes. Based on comprehensive evaluation, a diluent volume of 12 ml is considered more suitable than 6 ml for the dilution of colistin.

02

Conditions studied

  • Inhalation Pneumonia

Browse trials for

Keywords

  • Colistin
  • antibiotic
  • inhalation therapy
  • diluent volume
  • randomized controlled trial
03

In context

Pneumonia, Aspiration

73 studies on the registry are indexed under Pneumonia, Aspiration; 12 are open to participants now.

This study's planned enrollment of 60 is below the median of 113 across 38 interventional studies indexed under Pneumonia, Aspiration.

Browse Pneumonia, Aspiration studies →

Lead sponsor

Fu Jen Catholic University is the lead sponsor of 48 studies on the registry; 22 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Admitted to the Intensive Care Unit.
  • Age greater than 18 years and using a ventilator due to acute respiratory failure.
  • Requires inhalation colistin treatment as determined by the disease.
  • Sign the written form.

Exclusion criteria

Exclusion Criteria:

  • Renal failure requiring renal dialysis.
  • Receiving both inhaled colistin and intravenous colistin treatments.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
60 participants (estimated)

Study arms

  • Active comparator
    Colistin 1 MU in normal saline 1 ml

    1 MU of colistin in a total volume of 6 ml, diluted with a 1:1 ratio in normal saline (0.9%)

    Other: Colistin 1 MU in normal saline 1 ml

  • Experimental
    Colistin 1 MU in normal saline 2 ml

    1 MU of colistin in a total volume of 12 ml, diluted with a 1:2 ratio in normal saline (0.9%)

    Other: Colistin 1 MU in normal saline 2 ml

Interventions

  • OtherColistin 1 MU in normal saline 1 ml

    Colistin 1 MU diluted in normal saline 1 ml, total volume of 12 ml

  • OtherColistin 1 MU in normal saline 2 ml

    Colistin 1 MU diluted in normal saline 2 ml, total volume of 12 ml

06

What researchers measure

Primary outcomes

  1. Drug concentration

    Drug concentration in bronchoalveolar lavage fluid and blood

    Time frame: One hour post inhalation therapy with colistin on the third day of treatment

07

Study locations

1 of 1 sites recruiting
  • Fu Jen Catholic University Hospital, Fu Jen Catholic University
    New Taipei City, 24352, Taiwan
    Recruiting
    • Ke-Yun Chao, PhD · Contactck_qq@hotmail.com · +886-905-301-879
    • Ke-Yun Chao, PhD · Principal investigator
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Dec 2027, 45 months after the start.

Of 16 interventional studies with no phase under Pneumonia, Aspiration, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 31. This study's planned 45 months is above that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 9, 2026: primary completion Jul 2026 → Dec 2027 and completion Jul 2026 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 21, 2024
First posted
Jan 30, 2024
StartActual
Mar 10, 2024
Primary completionEst.
Dec 31, 2027was Jul 2026
CompletionEst.
Dec 31, 2027was Jul 2026
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jul 31, 2026→Dec 31, 2027
Nov 9, 2026
Study completion
Jul 31, 2026→Dec 31, 2027
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Primary completion Jul 31, 2026→Dec 31, 2027
    Study completion Jul 31, 2026→Dec 31, 2027

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06230614
Lead sponsor
Fu Jen Catholic University
Responsible party
Ke-Yun, Chao (Group leader of Respiratory Therapists, Fu Jen Catholic University) — Principal investigator
First posted
Jan 30, 2024
Start date
Mar 10, 2024
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Nov 9, 2026

Study contacts

Ke-Yun Chao, PhD
Contact
C00152@mail.fjuh.fju.edu.tw
+886-905-301-879
Ke-Yun Chao, PhD
principal investigator · Fu Jen Catholic University Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion